Friday 6 November 2026 Export PTGX’s income statement to Excel — free account

Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, down 89.4% from fiscal 2024.

Revenue: +3,749.2%
EPS: +549.1%
Free cash flow: +839.7%

Quarter to June 2026, against a year earlier

131.81 3.45 −2.55%

Follow PTGX

Alert me

Market cap: $8.8B
P/E: 108×
Fwd P/E: 31.2×
Dividend yield: —
F-score: 4/9
Altman Z: 61.55
Beneish M: −7.18
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Protagonist Therapeutics, Inc. (PTGX) P/E ratio

Alert me on P/E ratio

As of 6 November 2026, Protagonist Therapeutics, Inc. (PTGX) trades at a P/E ratio of 108×. Over the past ten years it has ranged from 0.0× (June 2026) to 130× (August 2026); the current reading is higher than 95% of that period. That is above the Biotechnology industry median of 10.6× and above the Healthcare sector median of 24.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/PTGX/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Protagonist Therapeutics, Inc. P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/PTGX/metrics/pe-ratio">Protagonist Therapeutics, Inc. (PTGX) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	0.0×	—
FY2024	8.6×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	0.0×	—

Period	P/E ratio	Change
Jun 2026	100×	—
Mar 2026	0.0×	—
Dec 2025	0.0×	—
Sep 2025	88.6×	33.01%
26 more quarters	Free account

Against its own ten years

Low 0.0× High 130×

Ten-year median 0.0×

Current reading's percentile 95

Company	P/E ratio
TWST Twist Bioscience Corporation compare	n/m
SYRE Spyre Therapeutics, Inc. compare	n/m
IBRX ImmunityBio, Inc. compare	n/m
MDGL Madrigal Pharmaceuticals, Inc. compare	n/m
ARWR Arrowhead Pharmaceuticals, Inc. compare	n/m
PCVX Vaxcyte, Inc. compare	n/m
TGTX TG Therapeutics, Inc. compare	19.6×
KRYS Krystal Biotech, Inc. compare	39.2×
PTGX Protagonist Therapeutics, Inc.	108×
Biotechnology industry median	10.6×
Healthcare sector median	24.5×
Market median	17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Protagonist Therapeutics, Inc. (PTGX) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on PTGX

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on PTGX

Stockrow Weekly